EP ERA4Health Call 2027 “Multi-national Investigator-Initiated Clinical Studies in Cardiovascular, Autoimmune, Metabolic, and Non-Communicable Respiratory Diseases, including Underrepresen­ted Populations”

The aim of the call is to support pragmatic, phase III, randomised controlled, multi-national interventional Investigator-Initiated Clinical Studies (IICS)

1. that are designed as following study types:

• comparative-effectiveness studies and/or
• drug repurposing studies of off-patent drugs

Applicants can make use of existing cohorts, e.g. for designing Trials within Cohorts (TwiCs).

2. that have a high public relevance in the fields of the following diseases or conditions (that are of equal importance):

• Cardiovascular diseases
• Metabolic disorders
• Autoimmune diseases
• Non-communicable respiratory diseases

The IICS should primarily address at least one of the abovementioned diseases/conditions, although a proposal can also address several of the mentioned diseases/conditions and/or in combination with related comorbidities.

3. that ensure inclusivity and diversity in the study population and also include sex/gender-sensitive, age-specific or other diversity-related aspects, if reasonable.

Important facts:

• 14.01.2027 – pre-proposal
• 14.06.2027 – full-proposal
• Min. 3 partner from 3 participating countries
• Max. 48 month project duration
• 600,000 – 800,000 EUR German funding per project

Participating countries:

Austria, Belgium, Czech Republic, Egypt, France, Germany, Ireland, Israel, Italy, Latvia, Lithuania, Norway, Poland, Romania, Slovakia, Spain, Sweden, Türkiye, United Kingdom

Important LINKs:

https://era4health.eu/calls/pre_iics4all2027.php